Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids

Abstract

Eczema, or atopic dermatitis, is a common, non-communicable, immune-mediated, inflammatory skin illness mainly affecting children. It is a chronic condition. It causes mental health problems like anxiety, sadness, anxiety, depression, hyperactivity, and obesity. It is the first skin ailment and the fifteenth non-fatal disease. The purpose of the present research study was to evaluate the Safety and Effectiveness of biological treatment for atopic dermatitis using monoclonal antibodies against non-biological treatment, including antibiotics, immunosuppressants, demards, histamine antagonists and corticosteroids. Patient information was gathered from FDA-approved clinical trials. The comparative analysis found that Biological therapies like Dupilumab, Omalizumab, and Ustekinumab improve symptoms and disease control in atopic dermatitis. Non-biological treatments may not be as effective. Early antibiotic exposure can increase infection vulnerability. Mild eczema infections require biological agents. Topical corticosteroids can be combined with Dupilumab for effective treatment of atopic dermatitis. Studies show that Dupilumab improves symptoms and quality of life, making it a better option than a placebo. FDA recommends using biological agents over immunosuppressants in paediatrics for improved immune results. FDA clinical trials showed that dupilumab is a safe and effective treatment for children with moderate-to-severe atopic dermatitis, reducing disease severity and improving quality of life in young AD patients.